GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced that the Arexvy vaccine (MAL24086007ARZ) has been approved in Malaysia for respiratory syncytial virus (RSV). RSV is a common respiratory ...
Arexvy has been approved in Malaysia for RSV (respiratory syncytial virus), for older adults aged 60 and above. The vaccine ...
Cancer Vaccines Market revenue is expected to hold around USD 24.22 billion by 2033 from USD 9 million in 2023 with a ...
(Alliance News) - GSK PLC on Tuesday announced a new positive opinion from the EU's European Medicine Agency's Committee for Medicinal Products for Human Use. The London-based pharmaceutical company ...
NewZNew - Sensodyne Celebrates World Dentist Day with #DoctorsOfJoy Campaign: Sensodyne, a leading oral care brand from ...
Analysts have been eager to weigh in on the Healthcare sector with new ratings on GlaxoSmithKline (GB:GSK – Research Report), Sonova Holding AG (CH:SOON – Research Report) and Corbus Pharmaceuticals ...
The 13 drugs most likely to be chosen for CMS negotiations, according to the study: Ozempic, Rybelsus and Wegovy (semaglutide): Novo Nordisk's treatment for Type 2 diabetes and weight management.
There hasn’t been a new class of drugs approved to help smokers quit since Pfizer's Chantix reached the market nearly two ...
The Gates Foundation-funded Gavi immunization programme introduced the GlaxoSmithKline (GSK) Mosquirix vaccine in three ...
IDEAYA Biosciences is a promising biotech company targeting genetic vulnerabilities in cancer cells with synthetic lethality.
Neoadjuvant therapy is an essential part of high-risk stage III resectable melanoma management, with combination ...
Bank of America Securities analyst Graham Parry maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) yesterday and set a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback